ChinaBio® Partnering Forum
2009 Announces Program Highlights
Carlsbad, USA, and Shanghai, China, June 5, 2009:
EBD Group and ChinaBio® LLC, today announced
that the first annual ChinaBio® Partnering
Forum 2009 partnering event, June 23–24 in Shanghai, China,
will host some of the biggest names in the international
biotech industry. Featured on panels and workshops, leading
decision makers will tackle the central issues for success
in China.
To learn more about any of the sessions below, please
visit the ChinaBio® Partnering Forum program
page at http://www.ebdgroup.com/cbpf/ws_panels.htm
Partnering in China—the New Frontier:
China has become a global hotbed of technology development
for big pharma. All of the large multinational companies
now have R&D centers in China, most based in Shanghai.
As its domestic industry rapidly evolves, China offers
a growing number of collaboration and partnering opportunities
with emerging companies, universities and institutes.
Moderator Greg Scott, President and Founder, ChinaBio®
LLC will be joined by speakers Dr. Mervyn Turner, Chief
Strategy Officer, Merck & Co., Inc; Dr. Samantha Du,
CEO, Hutchison MediPharma; and Liam Condon, Managing Director,
Bayer Healthcare China, to examine the key questions for
all pharma and biotech companies looking for partnering
opportunities in China.
Capital Outlook for China Biopharma:
The financial crisis has changed the international biopharmaceutical
landscape dramatically. In China, a unique set of circumstances,
including government funding, big pharma interest and
continued VC funding makes the current climate there more
positive than elsewhere in the world. Leading industry
financial experts Helen Chen, Partner and Head of China
Life Sciences, L.E.K. Consulting; Bo Wen, Executive Director,
The Balloch Group; Dr. Carl Firth, VP, Asia, Merrill Lynch;
and Dr, Chika Yoshinaga Yao, VP, Asia, Sofinnova Partners,
will review what opportunities and challenges the future
may hold for the dynamic growth region that is China.
China’s Outsourcing Revolution: Dwindling
pipelines and shrinking revenue are problems most pharmaceutical
companies are facing today. To make R&D more efficient,
many of them are building virtual development groups,
especially in China where costs are much lower. As a result,
the CRO/CMO industry is booming, and in fact, two of the
largest CRO facilities in the world are currently being
built in China. Dr. Wendy R. Jory, Services Segment Leader,
Discovery Services, Life Technologies will lead a panel
featuring Dr. Darren Ji, CEO, PharmaLegacy Laboratories
(Shanghai); Dr. Stephen Porter, CSO, Medicilon-MPI Preclinical
Research; and Dr. Dan Zhang, Chairman and CEO, Fountain
Medical Development, in an examination of the impact of
the outsourcing revolution in China and how it is creating
opportunities for increased productivity and collaborative
development projects as well as lowered costs.
Life Science Clusters in China—Where, What and
How: The China government has created a strong
financial stimulus to build a solid domestic biotech/biopharma
industry. This has resulted in the launch of several major
life science clusters throughout China. Officials and
executives from the top life science parks and agencies
in China, including Dr. Don Qiu, General Manager, ChinaBio®
LLC; Yuwen Liu, General Manager, BioBay; and Dr. Xiaolin
Wei, Vice General Manager, Shanghai Z.J. Biotech &
Pharmaceutical Base Development Co., will present the
advantages each region offers and specific incentive programs,
as well as a “where to” and “how to” approach to establishing
a presence in China.
From Research to Commercialization—Starting
at Square One: Commercializing early stage technology
is a challenge anywhere in the world. Starting with essentially
a clean sheet, China has the opportunity to do things
differently. This also means that there is little experience
and expertise at hand to draw from. A panel led by David
Flores, Co-founder, President and CEO, BioCentury Publications,
and featuring Alex Fowkes, Head of R&D, Asia, Pfizer;
Dr. Frank Grams, Executive Director, Asia, Roche Pharma
Partnering; Dr. Jennifer Hu, Director, Licensing and External
Research, Merck & Co., Inc.; and Dr. Yi Zhun Zhu,
Dean, School of Pharmacy, Fudan University, will examine
what is currently working in China, what is not, what
lessons can be gleaned from the experience in the US and
Europe, and how to be successful at moving technology
developed in China from the lab into the clinic.
Cross-border M&A and Strategic Alliances
in China—Opportunities and Challenges: China's
drug market is growing at an enormous speed and has become
an essential market for all big pharma and biotech players.
In addition to increasing direct investment into China,
overseas players have different initiatives and plans
in forming strategic alliances with local companies in
terms of R&D, manufacturing, commercialization and
service. Influenced by Chinese government incentives and
the tremendously growing talent pool, Chinese life science
companies are getting competitive on an international
level. As a consequence, more cross-border M&As will
also take place in this industry. Dr. Ruediger Herrmann,
Partner, WilmerHale, will lead a distinguished panel featuring
Dr. Carl Firth, VP, Asia, Merrill Lynch; Michael Heerde,
Head, Business Development, Bayer HealthCare China; Kewen
Jin, PhD, General Manager, Charles River Greater China;
and Dr. Victor Shi, Asia President, QIAGEN, to discuss
in detail what are the opportunities and challenges accompanying
such exciting transactions.
About ChinaBio® LLC
Since its founding in January, 2007, ChinaBio® LLC has
rapidly launched a number of successful initiatives connecting
China biotech with the world. With offices in Shanghai,
Silicon Valley and San Diego, ChinaBio®’s activities include:
- Conferences: Organizer of the premier life science
investment and partnering forums in China.
- Consulting: Helping big pharma, entrepreneurs and
investors achieve success in China.
- Accelerator: Assisting early stage China companies
to raise over USD 60 million to date.
- Research: Developing in-depth research data on novel
technology development, clinical trial activity, VC
investment, M&A/IPO and partnering activity in China.
- ChinaBio® Today: Publishing online and email newsletters
focusing exclusively on China’s life science industry.
About EBD Group
EBD Group is the leading partnering firm for the global
life science industry. Since 1993, biotech, pharma and
medical device companies have leveraged EBD Group’s partnering
conferences, technology and services to identify business
opportunities and develop strategic relationships essential
to their success.
EBD Group’s conferences are run with the support of leading
corporations and international trade associations and
include:
- BIO-Europe and BIO-Europe Spring®, the world's largest
stand-alone life science partnering conferences, supported
by the Biotechnology Industry Organization (BIO)
- BioPharm America™, EBD Group’s North American partnering
event
- EuroMedtech™, EBD Group’s new partnering event for
the innovative medical technology industry
- BioEquity Europe, the investor conference co-organized
with BioCentury Publications and BIO
EBD Group’s sophisticated web-based partnering service,
partneringONE™, is used as the partnering engine at numerous
third-party events around the world. Outside of the conference
format, EBD Group’s consultants provide hands-on assistance
for firms seeking to in- or out-license products and technologies.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com.
Contact:
In the USA
Constantine Theodoropulos
EBD Group
USA: +1 617 292 7319
ctheodoropulos@ebdgroup.com
In China
Jean Meng
ChinaBio LLC
China: +86 5137 0751
USA: +1 858 926 4566
jmeng@chinabiollc.com
